Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Journal of Neurosurgery. Case Lessons|September 20, 2023
Clinical diagnostic and radiographic features of recurrent intracranial malignant triton tumor in an adult: illustrative caseAjmain Chowdhury, Alex Belzer, Nahom Teferi, et al.
Cancer|February 17, 2026
A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanomaYousef Zakharia, Donghyun Kim, Michele Freesmeier, et al.
Oncotarget|November 29, 2017
Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb studyYousef Zakharia, Varun Monga, Umang Swami, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 5, 2021
Status of the Clinician Investigator in America: An Essential Healthcare Provider Driving Advances in Cancer CareRandall F Holcombe, Claire F Verschraegen, Andrew E Chapman, et al.
Redox Biology|October 26, 2017
Redox active metals and H2O2 mediate the increased efficacy of pharmacological ascorbate in combination with gemcitabine or radiation in pre-clinical sarcoma modelsJoshua D Schoenfeld, Zita A Sibenaller, Kranti A Mapuskar, et al.
Journal of Pain and Symptom Management|May 8, 2007
Jordan palliative care initiative: a WHO Demonstration ProjectJan Stjernswärd, Frank D Ferris, Samir N Khleif, et al.
Cancer Chemotherapy and Pharmacology|March 28, 2020
Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancerHani M Babiker, Mohammed Milhem, Joseph Aisner, et al.
Cancer Chemotherapy and Pharmacology|February 10, 2020
Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancerHani M Babiker, Mohammed Milhem, Joseph Aisner, et al.
Frontiers in Oncology|April 30, 2020
Functional Genomic Screening Independently Identifies CUL3 as a Mediator of Vemurafenib Resistance via Src-Rac1 Signaling AxisMarion Vanneste, Charlotte R Feddersen, Afshin Varzavand, et al.
Head & Neck|July 14, 2016
Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanomaRobert H I Andtbacka, Sanjiv S Agarwala, David W Ollila, et al.
Pageof 8